A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Type 1 Diabetes Mellitus

In brief

The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes. Based on results from other clinical trials with the study drug it was judged unlikely this study would meet the intended primary or secondary efficacy endpoints. Therefore the primary focus of this study was changed to ensure that safety data was available for at least 6 months following the last dose of active study drug. Thereafter the study was terminated.

Key facts

Study ID
NCT00751842
Run by
Diamyd Therapeutics AB
People needed
331
Starts
2008-09-01
Expected to finish
2012-07-01
Last updated by the study team
2012-10-10

Who can join

Age: 10 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.